Novo Nordisk A/S: Oral semaglutide 50 mg achieved 15.1% weight loss (17.4% if all people adhered to treatment) in adults with obesity or overweight in the OASIS 1 trial
Bagsværd, Denmark, 22 May 2023 – Novo Nordisk today announced headline results from OASIS 1,…